Teranga Pharma launches Drepaf sickle cell drug
Analysis based on 10 articles · First reported Aug 26, 2026 · Last updated Aug 26, 2026
The launch of Drepaf could disrupt the African sickle cell treatment market by offering a cheaper local alternative to imported hydroxyurea, potentially reducing costs for healthcare systems and patients. This may pressure existing suppliers like those of Hydrea and Siklos to lower prices, while boosting Teranga Pharma's growth prospects and regional influence.
Senegalese pharmaceutical firm Teranga Pharma has launched Drepaf, a generic hydroxyurea treatment for sickle cell disease, marking the first time this gold-standard medication is produced in Africa. The drug, available in adult and pediatric doses, aims to reduce painful crises and reliance on costly imports. Backed by 4 billion CFA ($7.1 million) in funding, Drepaf is already generating interest across West and Central Africa, with partnerships in Burkina Faso, Guinea, and Ivory Coast, and requests from the Democratic Republic of the Congo, Gabon, and Cameroon. The company, led by CEO Mouhamadou Sow, plans to meet demand across sub-Saharan Africa by 2030, strengthening regional pharmaceutical sovereignty. The launch addresses a critical shortage, as a 2023 study found frequent supply disruptions of hydroxyurea in 13 French-speaking African countries. Patient advocates like Magueye Ndiaye of the Senegalese Association for the Fight Against Sickle Cell Disease highlight the drug's affordability and improved access, particularly for children.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard